Iovance Biotherapeutics Beats Q4 Estimates as Amtagvi Sales Surge 33%

Iovance Biotherapeutics (IOVA) reported a narrower-than-expected loss for the fourth quarter, comfortably surpassing analyst estimates. The company's financial performance was bolstered by a significant 33% jump in sales for its flagship drug, Amtagvi, signaling strong commercial momentum. Beyond the balance sheet, Iovance shared positive clinical data showing a 50% Objective Response Rate (ORR) in its latest trials. Consequently, the firm plans to initiate a registrational study for its sarcoma treatment, further strengthening its clinical pipeline. These dual catalysts of earnings growth and pipeline progress triggered a surge in the company's stock price. Investors remain bullish on the company's trajectory as it successfully balances product commercialization with high-potential medical research.